PARP1 and neoplasm: Following extensive high-throughput drug screens using a library of compounds that are in (pre)clinical development for pediatrics, we found numerous potential synergistic combinations within each of the different malignancy types, including doxorubicin and cyclophosphamide which have previously demonstrated synergy when combined with PARP inhibition in some pediatric tumor types [10].